Literature DB >> 11127864

Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A.

B M Reipert1, R U Ahmad, P L Turecek, H P Schwarz.   

Abstract

To investigate the usefulness of factor VIII (FVIII) knockout mice as an animal model of hemophilia A, we characterized the antibody response in FVIII knockout mice to recombinant human FVIII, administered intravenously or subcutaneously with or without adjuvant, and compared results to those in normal mice. Anti-factor VIII antibodies were detected after both intravenous and subcutaneous administration, with the highest titers after subcutaneous administration plus adjuvant. Depending on the administration strategy. knockout mice formed antibodies more rapidly and developed higher titers of inhibitory antibodies (Bethesda) than normal mice, suggesting differences in epitope specificity. Blotting thrombin cleavage products separated by gel electrophoresis showed that both strains developed antibodies against the nonfunctional B domain as well as against functional domains of factor VIII. The antibodies were mainly of the IgG1 subclass and resembled type I antibodies in hemophilia A.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11127864

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  24 in total

1.  Gut dysbiosis modulates the immune response to factor VIII in murine hemophilia A.

Authors:  Julie Tarrant; Matthew Cormier; Kate Nesbitt; Courtney Dwyer; Christine Hough; David Lillicrap
Journal:  Blood Adv       Date:  2020-06-23

2.  Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice.

Authors:  Vivek S Purohit; C Russell Middaugh; Sathyamangalam V Balasubramanian
Journal:  J Pharm Sci       Date:  2006-02       Impact factor: 3.534

3.  Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicity.

Authors:  Vivek S Purohit; Sathyamangalam V Balasubramanian
Journal:  AAPS J       Date:  2006-05-26       Impact factor: 4.009

4.  Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex.

Authors:  Vivek S Purohit; Karthik Ramani; Rita Sarkar; Haig H Kazazian; Sathyamangalam V Balasubramanian
Journal:  J Biol Chem       Date:  2005-02-23       Impact factor: 5.157

5.  Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice.

Authors:  Dipak S Pisal; Matthew P Kosloski; C Russell Middaugh; Richard B Bankert; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2012-03-02       Impact factor: 3.534

6.  Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.

Authors:  Krithika A Shetty; Matthew P Kosloski; Donald E Mager; Sathy V Balu-Iyer
Journal:  Biopharm Drug Dispos       Date:  2016-09-13       Impact factor: 1.627

7.  Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo.

Authors:  Matthew P Kosloski; Krithika A Shetty; Hironao Wakabayashi; Philip J Fay; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2014-06-17       Impact factor: 4.009

8.  In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infection.

Authors:  J A Schroeder; Y Chen; J Fang; D A Wilcox; Q Shi
Journal:  J Thromb Haemost       Date:  2014-07-17       Impact factor: 5.824

9.  Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII.

Authors:  Matthew P Kosloski; Razvan D Miclea; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2009-06-05       Impact factor: 4.009

10.  The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice.

Authors:  John F Healey; Ernest T Parker; Rachel T Barrow; Travis J Langley; William R Church; Pete Lollar
Journal:  Thromb Haemost       Date:  2009-07       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.